| (Values in U.S. Thousands) | Mar, 2026 | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 |
| Sales | 1,140 | 1,740 | 1,930 | 1,970 | 2,600 |
| Sales Growth | -34.48% | -9.84% | -2.03% | -24.23% | -45.61% |
| Net Income | -6,210 | -3,300 | -3,100 | -5,930 | -5,740 |
| Net Income Growth | -88.18% | -6.45% | +47.72% | -3.31% | -108.73% |
China Sxt Pharmaceuticals Inc (SXTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
China SXT Pharmaceuticals Inc. is a pharmaceutical company. It is involved in research, development, manufacturing, marketing and sales of traditional Chinese medicine pieces including advanced TCMP as well as fine and regular TCMP products. China SXT Pharmaceuticals Inc. is based in Jiangsu, China.
Fiscal Year End Date: 03/31